The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://annielgsa049331.blog-gold.com/53704319/glp-3-retatrutide-a-comparative-analysis